Mark Connor

Professor

  • 4794 Citations
  • 39 h-Index
1991 …2019
If you made any changes in Pure these will be visible here soon.

Personal profile

Biography

I am Pharmacologist interested in analgesics and other psychoactive drugs, particularly cannabinoids and opioids. My lab studies how opioids, cannabinoids and related molecules interact with G protein coupled receptors and ion channels to exert their effects. Currently my work is focussed on how clinically used opioids interact with naturally occuring variants of human opioid receptors, the pharmacology and toxicity of emerging synthetic cannabinoid receptors agonists (Spice/K2) and the molecular mechanisms underlying the potential therapeutic actions of cannabis and its components.

Education/Academic qualification

Pharmacology, PhD, University of Washington

Pharmacology, Genetics, BSc (Hons), University of Sydney

Fingerprint Dive into the research topics where Mark Connor is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles
mu Opioid Receptor Medicine & Life Sciences
Opioid Analgesics Medicine & Life Sciences
Cannabinoids Chemical Compounds
Pharmacology Medicine & Life Sciences
Neurons Medicine & Life Sciences
Periaqueductal Gray Medicine & Life Sciences
Cannabinoid Receptor CB2 Medicine & Life Sciences
Cannabinoid Receptor Agonists Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2008 2019

Research Outputs 1991 2019

Cannabichromene is a Cannabinoid CB2 receptor agonist

Udoh, M., Santiago, M., Devenish, S., McGregor, I. & Connor, M., 1 Aug 2019, (Accepted/In press) In : British Journal of Pharmacology.

Research output: Contribution to journalArticleResearchpeer-review

Cannabinoid Receptor Agonists
Cannabinoid Receptor CB2
Cannabinoid Receptor CB1
Dronabinol
Cell Surface Receptors

Dark classics in Chemical Neuroscience: Δ 9 -tetrahydrocannabinol

Banister, S. D., Arnold, J. C., Connor, M., Glass, M. & Mcgregor, I. S., 15 May 2019, In : ACS Chemical Neuroscience. 10, 5, p. 2160-2175 16 p.

Research output: Contribution to journalReview articleResearchpeer-review

Dronabinol
Neurosciences
Cannabis
Medical Marijuana
Pharmacology

New-generation azaindole-adamantyl-derived synthetic cannabinoids

Longworth, M., Reekie, T. A., Blakey, K., Boyd, R., Connor, M. & Kassiou, M., Jul 2019, In : Forensic Toxicology. 37, 2, p. 350-365 16 p.

Research output: Contribution to journalArticleResearchpeer-review

Open Access
File
Cannabinoids
Ionization
Mass spectrometry
Assays
Mass Spectrometry

Regulation of heterologously expressed 5-HT1B receptors coupling to potassium channels in AtT-20 cells

Heblinski, M., Bladen, C. & Connor, M., 1 Feb 2019, In : British Journal of Pharmacology. 176, 3, p. 451-465 15 p.

Research output: Contribution to journalArticleResearchpeer-review

Receptor, Serotonin, 5-HT1B
Potassium Channels
Sumatriptan
Serotonin
G Protein-Coupled Inwardly-Rectifying Potassium Channels

Strategies to develop selective CB2 receptor agonists from indole carboxamide synthetic cannabinoids

Moir, M., Lane, S., Lai, F., Connor, M., Hibbs, D. E. & Kassiou, M., 15 Oct 2019, In : European Journal of Medicinal Chemistry. 180, p. 291-309 19 p.

Research output: Contribution to journalArticleResearchpeer-review

Cannabinoid Receptor CB2
Cannabinoids
Chemical activation
Designer Drugs
Cannabinoid Receptor CB1